MedTrace Logo

The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With Dementia

NCT02415062 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2015-08-06

No results posted yet for this study

Summary

The purpose of this study to evaluate the safety and efficacy of high-dose donepezil (23mg) in Parkinson's disease with dementia compared to standard dose donepezil.

Conditions

Interventions

DRUG

Donepezil

23mg/day for 24 weeks versus 10mg/day for 24 weeks

Sponsors & Collaborators

  • Inje University

    lead OTHER

Principal Investigators

  • Sangjin Kim, Professor · Inje University Haeundae Paik Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-10-31
Completion
2017-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02415062 on ClinicalTrials.gov